Drug Trial Radar · NCT03358875
Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)
Last checked: Nov 20, 2026Latest source record: Feb 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
805
Actual
Start
Nov 30, 2017
Primary completion
Jul 15, 2021
Study completion Jan 18, 2024
Sponsor
- Lead sponsor
- BeiGeneBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Dec 2, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to show that tislelizumab will improve overall survival in participants with Stage IIIB or IV non-small cell lung cancer when compared to docetaxel in second or third-line treatment setting.
Conditions
- Non-small Cell Lung Cancer
Interventions
TislelizumabDrug
Tislelizumab administered by intravenous (IV) infusion
DocetaxelDrug
Docetaxel administered as an IV infusion over 1 hour
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) in All Participants (Co-primary Endpoint)Time frame: From randomization to the data cutoff date of 10 August 2020; up to 32.4 months
- Overall Survival (OS) in Programmed Cell Death Protein Ligand-1 (PD-L1)-Positive Participants (Co-primary Endpoint)Time frame: From randomization up to the final efficacy analysis data cut-off date of 15 July 2021; Up to 43 months
Locations
121 sites in 10 countries. Site status is shown where the registry gives one.
Hospital de Amor Barretos
Barretos, Brazil
Hospital Evangelico de Cachoeiro de Itapemirim
Cachoeiro de Itapemirim, Brazil
Hospital Haroldo Juacaba Instituto Do Cancer Do Ceara
Fortaleza, Brazil
Oncosite Centro de Pesquisa Clinica Em Oncologia
Ijuí, Brazil
Fundacao Doutor Amaral Carvalho
Jaú, Brazil
Hospital Bruno Born
Lajeado, Brazil
Hospital Sao Vicente de Paulo
Passo Fundo, Brazil
Hgb Hospital Giovanni Battista Mae de Deus Center
Porto Alegre, Brazil
Hospital Sao Lucas Da Pucrs
Porto Alegre, Brazil
Hospital Nossa Senhora Da Conceicao
Porto Alegre, Brazil
Hospital de Clinicas de Porto Alegre
Porto AlegreRS, Brazil
Inca Instituto Nacional de Cancer
Rio de Janeiro, Brazil
Nob Nucleo de Oncologia Da Bahia
Salvador, Brazil
Cepho Centro de Estudos E Pesquisas de Hematologia E Oncologia
Santo André, Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto
São José do Rio Preto, Brazil
Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira
São Paulo, Brazil
Umhat Deva Maria, Eood
Burgas, Bulgaria
Mhat Dobrich, Ad
Dobrich, Bulgaria
Mhat Dr Tota Venkova, Ad
Gabrovo, Bulgaria
Complex Oncology Center Rousse Eood
Rousse, Bulgaria
Mhat For Womens Health Nadezhda, Ood
Sofia, Bulgaria
Acibadem City Clinic Mhat Tokuda Ead
Sofia, Bulgaria
Anhui Provincial Hospital
Hefei, Anhui, China
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Chinese Pla General Hospital
Beijing, Beijing Municipality, China
Beijing Chest Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Daping Hospital, Third Military Medical University
Chongqing, Chongqing Municipality, China
Cancer Center of Guangzhou Medical University
Guangzhou, Guangdong, China
Guangzhou Institute of Respiratory Disease
Guangzhou, Guangdong, China
Cancer Hospital of Shantou University Medical College
Shantou, Guangdong, China
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
The Affiliated Hospital of Zunyi Medical College
Zunyi, Guizhou, China
Hainan General Hospital
Haikou, Hainan, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
Hubei Cancer Hospital
Wuhan, Hubei, China
Showing 40 of 121 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.